Phosphorothioate-conjugated miRNAs for Synergistic Therapies
Legal Citation
Summary of the Inventive Concept
Integrating phosphorothioate-conjugated microRNAs with AI, IoT, blockchain, and novel materials to create more effective and personalized treatments for multiple myeloma and IL-6 signaling inhibition.
Background and Problem Solved
The original patent introduced phosphorothioate-conjugated microRNAs for treating multiple myeloma and inhibiting IL-6 signaling. However, these treatments lacked the ability to personalize treatment outcomes, track efficacy, and ensure secure patient data management. The new inventive concept addresses these limitations by combining the patented technology with synergistic technologies.
Detailed Description of the Inventive Concept
The new inventive concept integrates phosphorothioate-conjugated microRNAs with blockchain-based patient data management modules, artificial intelligence for predicting treatment outcomes, nanoparticle carriers made of biodegradable materials, and IoT-based monitoring devices. This synergy enables personalized medicine, secure data management, and real-time treatment efficacy tracking. The phosphorothioate-conjugated microRNAs are selected from the group consisting of let7a-3p miRNA, let7a-5p miRNA, miR17-3p miRNA, miR17-5p miRNA, and miR218-5p miRNA.
Novelty and Inventive Step
The new inventive concept's novelty lies in the integration of phosphorothioate-conjugated microRNAs with synergistic technologies, providing a more effective, personalized, and secure treatment approach. The inventive step is the unexpected combination of these technologies, which yields a more powerful system than the sum of its individual components.
Alternative Embodiments and Variations
Alternative embodiments may include the use of different microRNA sequences, varying nanoparticle carrier materials, or incorporating additional AI algorithms for treatment optimization. Variations may also include the application of this technology to other diseases or treatment areas.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the personalized medicine and cancer treatment markets, with potential applications in multiple myeloma, IL-6 signaling inhibition, and other disease areas. The integration of AI, IoT, and blockchain technologies also opens up opportunities for partnerships with technology companies and healthcare providers.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K47/549 |
| A | A61 | A61K47/548 |
| A | A61 | A61K48/00 |
| C | C12 | C12N15/113 |
| C | C12 | C12N2310/141 |
| C | C12 | C12N2320/30 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Molecular biology, nucleic acid therapeutics, with specific focus on microRNA conjugation and delivery technologies for targeted disease treatment, requiring advanced knowledge of biochemistry, molecular engineering, and pharmaceutical development
Person of Ordinary Skill (PHOSITA) Profile
A PhD-level researcher with expertise in molecular biology, experience in microRNA design, conjugation techniques, and drug delivery systems, familiar with emerging technologies in personalized medicine and biotechnology
Obviousness Rationale
A PHOSITA would recognize that integrating blockchain, AI, and IoT technologies with existing phosphorothioate-conjugated microRNA delivery methods represents a predictable extension of known therapeutic approaches. The combination of microRNA targeting with advanced digital technologies follows established trends in personalized medicine and precision healthcare. The technical variations disclosed represent incremental improvements using standard engineering techniques and known technological integration strategies.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,633 |
|---|---|
| Title | Phosphorothioate-conjugated miRNAs and methods of using the same |
| Assignee(s) | City of Hope |